Cost-Effectiveness Of Upcoming Diabetes And Asthma Drugs To Get ICER Reviews
This article was originally published in The Pink Sheet Daily
Executive Summary
ICER is likely to consider whether Novo Nordisk's Tresiba can be differentiated from other long-acting insulins and the potential size of the patient population for GlaxoSmithKline's asthma drug, Nucala.